Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
Latest Information Update: 08 Nov 2022
Price :
$35 *
At a glance
- Drugs Amphotericin B (Primary) ; Fluconazole (Primary) ; Flucytosine (Primary) ; Amphotericin B
- Indications Cryptococcal meningitis
- Focus Registrational; Therapeutic Use
- Acronyms EnACT3
- Sponsors Matinas BioPharma
- 02 Nov 2022 According to a Matinas Biopharma media release, enrollment is expected to take approximately 18 months, with topline data expected in the second half of 2024.
- 21 Sep 2022 According to a Matinas Biopharma media release, the company expect to initiate this trial in the first quarter of 2023.
- 19 Sep 2022 New trial record